VeraLight said the device needs no blood and does not require fasting.
The patient simply places forearm onto the portable table-top unit and a quantitative result is reported in about three minutes.
Scout DS measures skin fluorescence using proprietary technology to detect abnormal concentrations of advanced glycation endproducts (AGEs) which are diabetes-related biological markers found in skin.
Previous studies have shown the presence of skin AGEs correlate well with diabetes and are a predictor of the disease’s serious complications.
Analogous to a ‘diabetes odometer,’ AGEs are a sensitive metric for the cumulative damage the body has endured due to the effects of abnormally high blood sugar and oxidative stress.
Scout DS is slated for market introduction later this year in Canada and select countries outside of the US.
